Workflow
ADS Ratio Change
icon
Search documents
Tuniu Announces Plan to Implement ADS Ratio Change and Declares Cash Dividend
Prnewswire· 2026-03-20 10:00
Core Viewpoint - Tuniu Corporation plans to change the ratio of its American depositary shares (ADSs) from one ADS representing three Class A ordinary shares to one ADS representing thirty Class A ordinary shares, effective around April 22, 2026, and has declared a cash dividend of approximately US$13 million [1][2][6]. ADS Ratio Change - The ADS Ratio Change will effectively act as a one-for-ten reverse ADS split for existing ADS holders [2]. - Upon the Effective Date, ADS holders will exchange every ten existing ADSs for one new ADS, with JPMorgan Chase Bank, N.A. managing the exchange [3]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [4]. - The trading price of the Company's ADSs is expected to increase proportionately after the ADS Ratio Change, although no assurance can be given regarding the exact price increase [5]. Cash Dividend Declaration - The board of directors has approved a cash dividend of approximately US$13 million, payable to holders of ordinary shares and ADSs of record as of May 4, 2026 [6]. - The dividend for ordinary shares will be US$0.0399 per share, with payments expected around May 14, 2026, while the per ADS dividend will be disclosed after the ADS Ratio Change [6].
Foresight Announced ADS Ratio Change
Globenewswire· 2026-02-20 21:05
Core Viewpoint - Foresight Autonomous Holdings Ltd. plans to change the ratio of its American Depositary Shares (ADSs) from one ADS for thirty Ordinary Shares to one ADS for ninety Ordinary Shares, effective February 26, 2026 [1][2]. Group 1: ADS Ratio Change Details - The ADS Ratio Change will not affect the Company's Ordinary Shares [2]. - ADS holders will need to surrender their existing ADSs to receive one new ADS for every three existing ADSs [2][4]. - The ADSs will continue to trade on Nasdaq under the symbol "FRSX" with a new CUSIP Number after the change [3]. Group 2: Impact on Shareholders - The ADS Ratio Change will not impact any shareholder's percentage ownership or voting power [4]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [4]. Group 3: Price Expectations and Compliance - The Company anticipates that the ADS price will increase proportionally due to the ADS Ratio Change, although no assurance can be given regarding the actual price post-change [5]. - The change is intended to help maintain compliance with Nasdaq listing requirements, but the Company cannot guarantee this outcome [5]. Group 4: Company Overview - Foresight Autonomous Holdings Ltd. is focused on developing advanced three-dimensional perception and cellular-based applications through its subsidiaries [6]. - The Company's technology includes automatic calibration and dense 3D point cloud systems applicable in various markets such as automotive and defense [7].
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
Newsfilter· 2025-04-09 11:30
Core Viewpoint - Amarin Corporation is implementing a Ratio Change for its American Depositary Shares (ADS) to comply with Nasdaq's minimum bid price requirement, changing the ratio from 1 ADS representing 1 ordinary share to 1 ADS representing 20 ordinary shares, effective April 11, 2025 [1][2]. Group 1: Ratio Change Details - The Ratio Change aims to increase the per share market price of the Company's ADSs to meet Nasdaq's $1.00 minimum bid price requirement [2]. - The Company cannot guarantee that the trading price per ADS after the Ratio Change will be equal to or greater than twenty times the trading price per ADS before the Ratio Change [2]. Group 2: Impact on Ordinary Shares - The ordinary shares of Amarin Corporation will remain unaffected by the Ratio Change, and the ADSs will continue to trade on The Nasdaq Capital Market under the symbol "AMRN" [3]. Group 3: Company Overview - Amarin is an innovative pharmaceutical company focused on cardiovascular disease management, aiming to enhance the scientific understanding of cardiovascular risk beyond traditional therapies [3]. - The Company has offices in Bridgewater, New Jersey, Dublin, Ireland, Zug in Switzerland, and other European countries, along with commercial partners and suppliers globally [3].